Sofinnova Ventures

genengnews.com: Genetic Engineering genengnews.com

Pioneering Group of Emerging Medtech Companies Seek $240 Million in New Financing

genengnews.com     Aug 20, 2008          

News source: Business Wire Life Science Intelligence (LSI) announced this month that another new group of 31 mostly privately-held medtech companies has recently been added to the EMT (Emerging Medical Technologies)(R)...                    

comments

Anthera gets $19M new funding (at bizjournals.com)

yahoo.com     Aug 14, 2008   1 related          

Silicon Valley / San Jose Business Journal , a privately held biopharmaceutical company developing anti-inflammatory drugs, received $19 million in new funding. The San Mateo-based company said the round was led by New...                    

comments

genengnews.com: Genetic Engineering genengnews.com

Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney As Chairman

redorbit.com     Aug 13, 2008   6 related          

Posted on: Wednesday, 13 August 2008, 09:01 CDT SAN MATEO, Calif., Aug. 13 /PRNewswire/ -- Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the...                    

comments

                   
nsti.org: Nano Science and Technology Institute - NSTI nsti.org

MRAM startup qualifies production

eetimes.com     Aug 12, 2008   4 related          

SAN JOSE, Calif. -- Crocus Technologies Inc. claims that it has qualified its manufacturing environment for the development and prototyping of its MRAM technology. Based on a 130-nm CMOS process, Crocus' MRAM is being made at...                    

comments

livemint.com: Stimulating plan: M.J. Aravind, a partner at Artiman Ventures. (Photo: Hemant Mishra/Mint) livemint.com

VC firm sets up incubation centre in India to spot fundable start-ups

livemint.com     Aug 11, 2008          

Mumbai: In a bid to spot more fundable product start-ups here in India, Palo Alto, California-headquartered venture capital firm Artiman Ventures is building its focus around what it calls an entrepreneur-in-residence (EIR)...                    

comments

                   

Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer (PR...

yahoo.com     Aug 5, 2008   2 related          

Tuesday August 5, 8:00 am ET BRANFORD, Conn., Aug. 5 /PRNewswire/ -- Marinus Pharmaceuticals, a developer of specialty therapeutics to treat serious neurological, psychiatric and pain disorders, has appointed John Krayacich as...                    

comments

InteKrin Therapeutics Announces $20 Million Series C Financing

prnewswire.com     Aug 4, 2008   1 related          

LOS ALTOS, Calif., Aug. 4 /PRNewswire/ -- InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of products for diabetes, metabolism and obesity today announced it has completed the...                    

comments

Novel Group of Emerging Medtech Companies Seek $135.5M in New Financing

tmcnet.com     Jul 10, 2008   1 related          

HUNTINGTON BEACH, Calif. --(Business Wire)-- Life Science Intelligence (LSI) announced this month that another new group of 44 mostly privately-held medtech companies has recently been added to the EMT (Emerging Medical...                    

comments

                   

Movetis' Second Most Advanced Product Progresses to Phase IIb Trial Following Positive Results in...

yahoo.com     Jul 3, 2008   8 related          

Movetis NV, a European specialist pharmaceutical company, today announced that M0002 is progressing to phase IIb following positive results of a phase IIa multiple-dosing trial for the treatment of ascites, the accumulation of...                    

comments

Dutton Associates Announces Investment Opinion: Amarin Rating Maintained At Speculative Buy By...

yahoo.com     Jun 24, 2008   3 related          

ROSEVILLE, Calif.----Dutton Associates continues coverage of Amarin Corporation plc , maintaining its rating at Speculative Buy and its $7.00 price target. The 11-page report by Dutton senior analyst Stephen Handley is...                    

comments

1 2 3 4 next »